Treatment Strategy of Intimal Hyperplasia Based on Resolution of Inflammation: Promised Future of Specialized Lipid Mediators

Abstract

After revascularization, intimal hyperplasia is based on inflammation and involves vascular smooth muscle cell migration and proliferation. We focused on anti-inflammatory specialized lipid mediators (SPM) such as resolvin, an unsaturated fatty acid metabolite that has an inflammation-converging effect. Although SPM is promising, it requires a proper drug delivery system (DDS) targeted at the lesion site to construct a therapeutic system because it owns fragile property. Nucleic acids having anti-inflammatory action will also be discussed from the viewpoint of anti-inflammatory action and DDS.